The multidisciplinary team at Johns Hopkins is dedicated to providing the best cutting-edge care to our patients with a neuroendocrine tumor. The team includes highly-experienced surgeons, radiologists, interventional radiologists, pathologists, medical oncologists, radiation oncologists, gastroenterologists and geneticists supported by a dedicated team of nurses, nurse practitioners and physician assistants. Members of our team are recognized as international experts in their fields, and the team at Johns Hopkins was recently awarded the "Team Science Award," from the American Association for Cancer Research. Most importantly, we are dedicated to our patients.
The complexities of neuroendocrine tumors are best managed by caregivers with extensive experience. The disease demands it, and the team at Johns Hopkins has the experience needed. For example, neuroendocrine tumors often arise in the pancreas, and surgeons at Johns Hopkins have performed over 3,000 pancreatic resections, more than any other institution in the world. This experience matters, as a number of studies have shown that surgical volume (the number of pancreatic resections a center performs each year) is a strong predictor of patient outcome.
In an exciting advance, the FDA today approved Lutetium for the treatment of neuroendocrine tumors, including neuroendocrine tumors of the pancreas. Lutetium is a peptide receptor radionucleotide therapy. It targets somatostatin receptor positive neuroendocrine tumors. The approval is based on a randomized phase 3 clinical trial. Click here to learn more!